Promontory Therapeutics
Company Details
Status: Private
Employees: 11-50
Location:
New York, United States
Type:
sample
Technology:
sample
About: Promontory Therapeutics is a private, clinical stage biopharmaceutical company founded in 2010, and funded by private investors and family investment offices in the U.S., Europe and Asia. It holds the exclusive, global license to phosphaplatins, a family of novel agents currently in clinical development for the treatment of both solid tumors and hematological cancers. Phosphaplatins are the result of over 20 years of work by the inventor, and uniquely combine an immunological form of apoptosis with an attractive safety profile. The lead agent is the subject of two approved IND applications with the US FDA, and of a collaboration and option agreement for rights in Greater China with SciClone Pharmaceuticals.
Unlock access to company contacts, hot leads, and drug pipelines.
Log in or create a free account now!
Promontory Therapeutics | Active clinical trials on ClinicalTrials.gov
Active Clinical Trials Count | 0
No Active Trials Found On ClinicalTrials.gov.